With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis ...

Vertex Pharmaceuticals today announced that the European Commission has granted approval for Alyftrek ...

Vertex Pharmaceuticals (VRTX) on Tuesday announced that the European Commission has granted approval for Alyftrek for the ...

VRTX slips 9% in three months on slow new drug uptake and pipeline hiccups, but CF strength and 2025 growth offer a reason to ...

In terms of liquidity and interest, the mean open interest for Vertex Pharmaceuticals options trades today is 82.0 with a ...

NEW YORK – Drugmakers will soon be able to compete for a new accelerated review program established this week by the US Food and Drug Administration aimed at therapeutic programs that align with ...

Number of Hedge Fund Holders as of Q1: 60 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is one of the 10 biotech stocks screaming a buy. On June 17, RBC Capital reiterated a Sector Perform ...

Stavros made headlines in 2019 when she fought to receive a breakthrough treatment, Trikafta, when she was being considered for a double-lung transplant. “The decision to fight was the most courageous ...

Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally.

Prior to joining the Company, Dr. Bailey served as Medical Director at Vertex Pharmaceuticals, Inc. (Vertex), where he led the US launch of the prescription drug TRIKAFTA® for the treatment of ...

I was 8 years old, standing in our family dining room with my dad, setting the table for my baby sister Jill's 2nd birthday celebration. Always older than my years, I remember so clearly saying to my ...